This section of the site includes press releases and statements issued by the MHRA.
The opening hours for the Press Office are Monday to Friday between 9:00 and 17:00.
The Press Office
151 Buckingham Palace Road
Main telephone: 020 3080 7651
Out of hours: 07770 446 189
For urgent calls outside these press office hours please contact the duty press officer on : 07770 446 189.
We now have a Twitter channel for press releases and news statements, giving you another way to find out the latest news from the MHRA in real time.
Press enquiries should be made through the Press Office.
Latest press releases
17 Dec 2014 | Press Release: Faulty insulin pens recall
People with diabetes who use insulin pens manufactured by Owen Mumford are today being warned by the Medicines and Healthcare products Regulatory Agency (MHRA) to check if they have an affected lot. If they have a pen from the list of affected lots, then they should stop using them and receive a replacement at the earliest opportunity.
26 Nov 2014 | Regulator helps to create new cancer medicine facility
A brand new facility that ensures the continued supply of a critical cancer medicine forms the basis of the first case study released from the Innovation Office today at the Medicines and Healthcare products Regulatory Agency (MHRA). This new technology features a unique sterile manufacturing process that can help to treat patients with prostate and breast cancer.
25 Nov 2014 | Press release: Yellow Card Scheme looks to the future at 50th anniversary forum as MHRA signs up to safety
The Medicines and Healthcare products Regulatory Agency (MHRA) today hosted an expert stakeholder forum to develop a future roadmap for the Yellow Card Scheme, as the adverse reaction reporting system celebrates its 50th anniversary.
03 Nov 2014 | Press Release : Professor Sir Michael Rawlins appointed Chair of Medicines and Healthcare Products Regulatory Agency
The Medicines and Healthcare Products Regulatory Agency today announced the appointment of Professor Sir Michael Rawlins as its new Chair. He will take up post formally from 01 December 2014 and his appointment will be for three years.
MHRA today announced the UK’s biggest ever single seizure of smart drugs, also known as cognitive enhancers or nootropics. With over 20,000 units, of 13 different types of cognitive enhancement medicines. The seizure represents an approximate value of £200,000.
17 Oct 2014 | Press release: Regulator warns dentists about the dangers of buying and using counterfeit and unapproved dental equipment
The Medicines and Healthcare products Regulatory Agency (MHRA) is warning dentists about the potential danger of buying and using counterfeit and unapproved dental equipment. This follows the seizure of over 12,000 different pieces of poor quality dental equipment imported into the UK from China and Pakistan and sold on auction websites such as eBay, Amazon and Alibaba in the past 6 months.
17 Oct 2014 | MHRA statement on misuse of laxatives
MHRA has issued a statement following the BBC Watchdog investigation into the availability of stimulant laxatives in the UK, first broadcast on Thursday 16 October.
13 Oct 2014 | Press release: ‘One stop shop’ for advice on regenerative medicine opening for business
A new ‘one stop shop’ that will provide regulatory advice for those working in the life sciences industry on exciting regenerative medicines has been launched today.
10 Oct 2014 | Press release: MHRA responds to European Medicines Agency recommendations on the use of valproate medicines
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended strengthening the restrictions on the use of valproate medicines due to an increased risk of birth defects and developmental problems in children exposed to valproate in the womb.
The National Institute for Biological Standards and Control (NIBSC), a centre of the Medicines and Healthcare Products Regulatory Agency (MHRA), has signed an agreement with University College London (UCL) to maximise and further promote scientific collaboration in the field of advanced therapies.